Inhibitior of Bcl6 by FX1 protects DSS induced colitis mice through anti-inflammatory effects
The experimental findings demonstrate the inhibitory effect of FX1 on inflammation in murine colitis model as well as its potential mechanism. BCL6 is a potential target for treating IBD.
Authors
- Yimeng Xia (ORCID: https://orcid.org/0000-0001-5187-657X)
- Yijia He
- Chuan Zhou (ORCID: https://orcid.org/0009-0000-3693-265X)
- Muhan Zhang
- Junzhi Yu (ORCID: https://orcid.org/0000-0002-6347-572X)
- Yan Liu (ORCID: https://orcid.org/0000-0002-8193-6729)
- Yao Yao (ORCID: https://orcid.org/0000-0002-6723-6152)
- Binbin Wang (ORCID: https://orcid.org/0000-0002-1597-5930)
- Zhe Zhang (ORCID: https://orcid.org/0000-0001-7338-7718)
- Yaxing Sun
- Ruixian Liu (ORCID: https://orcid.org/0000-0002-8255-0887)
- Baisui Feng (ORCID: https://orcid.org/0000-0001-9440-9285)
- Yanru Zhang
- Shiyang Ning
Institutions
- Second Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-09
- DOI
- https://doi.org/10.3389/fimmu.2025.1558845
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00